Metacrine, Inc.

3985 Sorrento Valley Blvd
Suite C
San Diego
CA
92121
United States

About Metacrine, Inc.

We are a clinical-stage biopharmaceutical company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal, or GI, diseases. Our most advanced program is focused on the farnesoid X receptor (FXR) an important drug target in multiple liver and GI diseases. We have leveraged our chemistry and biology platform to internally discover a proprietary portfolio of non-bile acid FXR agonists. We purposefully designed MET409, our lead product candidate, to be an optimized, next-generation FXR agonist that we are initially developing as a potentially differentiated and best-in-class treatment for nonalcoholic steatohepatitis (NASH). In addition, we plan to evaluate MET409 as a potential first-in-class treatment for irritable bowel syndrome with diarrhea (IBS-D), and inflammatory bowel diseases (IBD), such as ulcerative colitis and Crohn’s disease. Beyond our FXR program, we are building a pipeline of novel drug candidates against other drug targets by taking advantage of our drug discovery and development capabilities.

37 articles with Metacrine, Inc.

Metacrine to Present New Preclinical Data in Inflammatory Bowel Disease (IBD) at European Crohn’s and Colitis Organisation (ECCO) 2021 Virtual Congress

7/6/2021

Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced that it will present new preclinical data at the European Crohn’s and Colitis Organisation (ECCO) 2021 Virtual Congress on July 9, 2021.
Metacrine and Its Partners to Present Data at the EASL International Liver Congress™ 2021

6/17/2021

Metacrine, Inc. today announced that it will present data at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2021, being held virtually from June 23-26, 2021.
Metacrine Achieves Full Enrollment for MET409 Phase 2a Combination Trial in Patients With Type 2 Diabetes and NASH

6/2/2021

Metacrine, Inc., a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, announced that it has completed enrollment for its Phase 2a trial evaluating MET409 in combination with empagliflozin, a sodium-glucose cotransport-2 inhibitor, in patients with type 2 diabetes and non-alcoholic steatohepatitis.
Metacrine to Present at 2021 Jefferies Healthcare Conference

5/26/2021

Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced that Preston Klassen, M.D., MHS, president and chief executive officer, will present virtually at the 2021 Jefferies Healthcare Conference at 11:00 a.m. ET on Friday, June 4, 2021
Metacrine to Present New Preclinical Data on MET642 in Inflammatory Bowel Disease at Digestive Disease Week 2021 Virtual Meeting

5/19/2021

Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced that it will present new preclinical data demonstrating the synergistic effect of MET642, a farnesoid X receptor (FXR) agonist, when combined with tofacitinib, a JAK inhibitor, in improving inflammatory bowel disease (IBD) at Digestive Disease Week (DDW) 2021.
Metacrine Achieves Enrollment Target for MET642 Phase 2a Trial Interim Analysis

5/18/2021

Metacrine, Inc., a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, announced it has enrolled the first 60 patients in its MET642 Phase 2a trial.
Metacrine Accelerates MET409 Clinical Development Milestone and Reports First-Quarter 2021 Results

5/13/2021

Topline results from a Phase 2a trial of MET409 in combination with empagliflozin in patients with NASH and type 2 diabetes now expected in the fourth quarter of 2021
Metacrine to Present at 2021 RBC Global Healthcare Conference

5/11/2021

Metacrine, Inc., a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, announced that Preston Klassen, M.D., MHS, president and chief executive officer, will present virtually at the 2021 RBC Global Healthcare Conference at 5:25 p.m. ET on Tuesday, May 18, 2021.
Metacrine Appoints Dr. Julia C. Owens to Its Board of Directors

4/5/2021

Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced the appointment of Julia C. Owens, Ph.D. to the Company’s board of directors, effective April 1, 2021. Dr. Owens will serve as a member of the Compensation Committee.
Metacrine Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results

3/18/2021

Topline Results from a Phase 2a Trial of MET409 in Combination with Empagliflozin in Patients with NASH and Type 2 Diabetes Expected in the First Half of 2022
Metacrine to Present Final Results from Phase 1 Trial of MET642, an Optimized FXR Agonist, at the 2021 NASH-TAG Conference

3/11/2021

Sustained pharmacodynamic effects with once-daily oral dosing, without increases in LDL cholesterol or pruritus at any dose level in healthy volunteers
Metacrine Announces Date of Fourth Quarter and Full Year 2020 Financial Results Conference Call

3/11/2021

Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that management will host a conference call and webcast to discuss its fourth quarter and full year 2020 financial results and other business highlights on Thursday, March 18, 2021 at 8:30 a.m. ET.
Metacrine Initiates Phase 2a Trial of MET642 for the Treatment of Patients with NASHOn-track for Interim Analysis Readout in the Fourth Quarter of 2021

3/9/2021

Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that the first patient has been treated in its Phase 2a trial of MET642, a potent, sustained, non-bile acid farnesoid x-receptor (FXR) agonist, for the treatment of patients with non-alcoholic steatohepatitis (NASH).
Metacrine to Present at H.C. Wainwright 2021 Global Life Sciences Conference

3/2/2021

Metacrine, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, announced that Preston Klassen, M.D., MHS, president and chief executive officer of Metacrine, will present at the H.C. Wainwright 2021 Global Life Sciences Conference, being held March 9-10, 2021.
Metacrine to Present at SVB Leerink 10th Annual Global Healthcare Conference

2/19/2021

Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that Preston Klassen, M.D., MHS, president and chief executive officer of Metacrine, will present at the SVB Leerink 10th Annual Global Healthcare Conference
Metacrine Announces Publication of MET409 NASH Proof-of-Concept Study Results in the Journal of Hepatology

2/16/2021

Publication highlights the first clinical evidence that the risk-benefit profile of FXR agonists can be enhanced through structural optimization
Metacrine Announces FDA Fast Track Designation for MET642 as a Treatment of NASH

1/19/2021

Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that the U.S. Food & Drug Administration (FDA) has granted Fast Track designation to MET642, the company’s second farnesoid X receptor (FXR) agonist, for the treatment of non-alcoholic steatohepatitis (NASH).
Metacrine Initiates Phase 2a Combination Trial of MET409 with Empagliflozin in Patients with Type 2 Diabetes and NASH

1/5/2021

Trial Designed to Evaluate Potential of FXR-Based Combination Therapy in a Growing Segment of NASH Patient Population with Significant Unmet Needs
Metacrine Reports Positive Results from Phase 1 Trial of MET642

12/17/2020

MET642 Demonstrated Sustained Pharmacokinetic Profile and Robust FXR Target Engagement with Once-Daily Oral Dosing, without Pruritis or LDL-Cholesterol Increase Doses Selected for Phase 2a Trial in Patients with NASH; On-Track to Initiate in 1H21
Metacrine to Participate in Upcoming Investor Conferences

11/23/2020

Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that Preston Klassen, M.D., MHS, president and chief executive officer of Metacrine, will present at the following December investor conferences